NewAmsterdam Pharma Income Statement (2022-2025) | NAMS

Income Statement Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 8.63M1.72M2.94M0.80M1.40M2.28M29.11M12.77M2.98M19.14M0.35M
Operating items
Research & Development 40.42M34.34M43.37M41.29M42.43M38.38M35.70M34.90M44.75M27.52M30.97M
Selling, General & Administrative 8.06M9.86M9.13M10.59M14.45M16.48M18.41M21.11M27.15M27.26M24.52M
Other Operating Expenses -0.00M
Operating Expenses 48.48M44.20M52.50M51.88M56.88M54.85M54.11M56.00M71.90M54.78M55.49M
Operating Income -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M
EBIT -39.85M-42.48M-49.56M-51.07M-55.48M-52.58M-25.00M-43.23M-68.92M-35.63M-55.14M
Non-operating items
Interest & Investment Income 0.94M4.61M3.06M2.67M3.08M4.87M4.44M4.49M7.35M7.05M6.71M
Other Non Operating Income 3.07M-0.07M-3.15M10.18M30.25M-6.60M4.68M19.57M-13.76M8.63M23.79M
Net income details
EBT -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Tax Provisions -0.00M
Profit After Tax -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Income from Continuing Operations -42.02M-38.29M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Consolidated Net Income -42.02M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Income towards Parent Company -42.02M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Net Income towards Common Stockholders -42.02M-47.13M-49.47M-93.77M-39.01M-16.65M-92.18M-39.53M-17.36M-72.00M
Additional items
EPS (Basic) -0.51-0.47-0.57-0.60-1.06-0.41-0.18-0.95-0.34-0.15-0.61
EPS (Weighted Average and Diluted) -0.51-0.47-0.57-0.60-1.06-0.41-0.18-0.95-0.34-0.15-0.61
Shares Outstanding (Weighted Average) 0.981.00
Shares Outstanding (Diluted Average) 0.981.00
EBITDA -42.02M-38.29M-47.13M-49.49M-93.77M-39.01M-16.65M-92.13M-39.56M-17.47M-71.69M
Shares Outstanding 83.21M81.77M82.32M82.47M82.47M89.72M90.02M92.17M108.06M112.17M112.51M113.17M
Tax Rate 0.01